Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Mann J, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S, Vilsboll T, Wolthers B, Perkovic V (2021)
Publication Type: Journal article
Publication year: 2021
Journal
DOI: 10.1111/dom.14443
Abstract
Aims: To investigate whether effects on chronic kidney disease risk factors could explain the apparent reduction in kidney outcomes (composite of macroalbuminuria, doubling of serum creatinine, renal replacement therapy, or renal death), primarily driven by changes in albuminuria, after treatment with the glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide in patients with type 2 diabetes in the LEADER and SUSTAIN 6 trials.
Involved external institutions
University of North Carolina at Chapel Hill
United States (USA) (US)
Novo Nordisk A/S
Denmark (DK)
University of Toronto
Canada (CA)
AdventHealth
United States (USA) (US)
Steno Diabetes Center
Denmark (DK)
University of New South Wales (UNSW)
Australia (AU)
United States (USA) (US)
Novo Nordisk A/S
Denmark (DK)
University of Toronto
Canada (CA)
AdventHealth
United States (USA) (US)
Steno Diabetes Center
Denmark (DK)
University of New South Wales (UNSW)
Australia (AU)
How to cite
APA:
Mann, J., Buse, J.B., Idorn, T., Leiter, L.A., Pratley, R.E., Rasmussen, S.,... Perkovic, V. (2021). Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes Obesity & Metabolism. https://doi.org/10.1111/dom.14443
MLA:
Mann, Johannes, et al. "Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis." Diabetes Obesity & Metabolism (2021).
BibTeX: Download